Form 4: BridgeBio Pharma Chief Accounting Officer Reports Tax Obligation Fulfillment
SEC Form 4 Filing
Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, reports the withholding of shares to cover tax obligations related to vested restricted stock units.
Summary
- On May 16, 2025, Maricel Apuli, the Chief Accounting Officer of BridgeBio Pharma, Inc. (BBIO), had 4,780 shares of common stock withheld to satisfy tax obligations.
- This action was related to the vesting of 9,408 shares of common stock underlying restricted stock units.
- Following the transaction, Apuli directly owns 142,859 shares of BridgeBio Pharma, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a standard transaction related to tax obligations, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, ensuring fair market practices.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of transaction where shares were withheld to satisfy tax obligations. |
| 05/20/2025 | Date of signature for the report. |
Keywords
Form 4, Beneficial Ownership, BridgeBio Pharma, BBIO, Maricel Apuli, Chief Accounting Officer, Tax Obligation, Restricted Stock Units, Share Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.